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A double-blind crossover trial was performed to assess
the effect of metoprolol in 10 patients (mean age 55 years)
with severe dilated cardiomyopathy. All patients clini-
cally had idiopathic dilated cardiomyopathy; however,
at coronary angiography, four had occult coronary djs-
ease. All were in New York Heart Association functional
class III with a left ventricular ejection fraction less than
35% as assessed by rest radionuclide ventriculography.
Studies were performed before treatment, after 4 weeks
of metoprolol therapy and after 4 weeks of placebo
administration. Erect bicycle sprint exercise was used
to determine maximal work load. Hemodynamic vari-
ables and radionuclide left ventricular ejection fraction
were recorded at rest and during graded supine bicycle
exercise. Cardiac medications were unchanged through-
out the trial.
The mean (± standard error of the mean) dose of
metoprolol was 130 ± 13 mg/day. Metoprolol did not
change symptoms, chest X-ray findings or exercise tel-
Cardiac failure has generally been considered a contram-
dicanon to the use of beta-adrenergic blocking therapy Re-
cently. several reports from Sweden (1-4) have suggested
that chronic beta-adrenergic blocking therapy Improved the
cardiac function of patients With severe Idiopathic dilated
cardiomyopathy, increased longevity and produced adverse
climcal effect s on withdrawal These studies were uncon-
trolled and nonrandormzed, however, and they relied on
noninvasive assessment of cardiac function at rest Contro-
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erance (baseline 700 ± 73, placebo 690 ± 85, metoprolol
710 ± 81 kilopond-meters [kpm]/min). Metoprolol
produced a significant decrease in heart rate at rest and
during exercise (p < 0.001). Mean blood pressure and
left ventricular filling pressure did not differ significantly
in the baseline, placebo and metoprolol studies. There
was a slight, but significant (p < 0.05) decrease in car-
diac index with metoprolol compared with placebo and
baseline studies. The small, but significant increase in
left ventricular ejection fraction from baseline to the
metoprolol and placebo studies (p < 0.001) was consid-
ered a result of spontaneous improvement rather than
of therapy. No significant differences were found be-
tween the patients with and without coronary disease.
In this study of patients with stable severe dilated
cardiomyopathy on vasodilator therapy, 1 month of
therapy with metoprolol did not result in symptomatic
or hemodynamic improvement.
vers y rem ains regarding this therapy for patients With severe
dtlated cardiomyopathy
The present study was designed to assess the effect on
cardiac function of I month of therapy with the cardio-
selective beta-adrenergic blocking drug , metoprolol, m a
group of patients With severe dilated cardiomyopathy that
was chmcally Idiopathic Symptomatic status, exercise tol-
erance, rest and exercise hemodynamics and left ventncular
ejection fracnon at rest and dunng graded supine exercise
were assessed
Methods
Study group (Table 1). Ten patient s who met the fol-
lowmg cntena entered the study I) a chmcal diagnosis of
severe idiopathic dilated cardiomyopathy With no history of
excessive alcohol intake. myocardial mfarcnon or anginal
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Table 1. Patient Description"
Rest
Metoprolol
Age (yr) Coronary Symptom LVEF Dosage Plasma
Case &Sex Angiogrphy Duranon (%) (rng) Level (ng/ml) Other Medications
66 M CAD/3VD 6 months 18 50 bid Digoxin, furosemide, hydralazme,
nitrates
2 69 M CAD/2VD 3 years 25 50 bid Digoxin, furosemide. prazosm, nitrates
3 41 M CAD/3VD 6 months 26 50 bid Digoxin. chlotnde, prazosm
4 53 M Normal 6 month 32 50 bid Digoxin, furosemide, prazosm, nitrates
5 59 M Normal 6 months 35 50 lid Furosemide, prazosm
6 44 F Normal I year 34 50 bid 20 Digoxm, furosemide, prazosm, mtrates,
spironolactone
7 52 M Normal 3 years 27 50 lid 105 Digoxin. furosemide, prazosm
8 64M Normal 3 years 25 100 bid 90 Digoxin, furosemide, prazosm
9 50 F Normal 4 years 12 50 bid 50 Drgoxm, furosemide. prazosm, nitrates
10 52 M CAD/2VD 2'/2 years 15 100 bid 134 Digoxin, furosemide, prazosm, nitrates,
spironolactone
*All patients had cluucally idiopathicdilated cardiomyopathy, m the four patients with coronary artery disease at coronary angiography. the disease
was chrncally occult
bid = twice a day, CAD = coronary artery disease, LVEF = radionuclide left ventncular ejection fracnon attnal entry, lid = three limes a day,
3VD = tnple vessel disease, 2VD = double vessel disease, = data not obtained
chest pam and no electrocardiographic changes to suggest
pnor myocardial mfarction, 2) classification rn New York
Heart Association functional class III with symptoms of at
least 3 months' duration; 3) sinus rhythm with a heart rate
at rest greater than 85 beats/min, 4) a chronic stable con-
dition, 5) left ventncular ejection fraction less than 35% on
rest radionuchde ventriculography and M-mode echocardi-
ography; and 6) left ventncular dilation and diffuse Im-
pairment of contraction demonstrated by radionuchde ven-
tnculography performed m multiple projections, there was
no focal dyskinesia or aneurysmal change in any patient to
suggest pnor myocardial mfarction
Our study group consisted of eight men and two women
with a mean age of 55 years (range 41 to 69) The mean
duration of symptoms was 1 9 years (range 6 months to 3
years) All patients had at least one previous episode of
overt cardiac failure requmng hospital admission Medi-
cations for heart failure were unchanged for at least 3 weeks
before entry into the tnal and throughout the tnal
After completion of the trial, coronary angiography was
performed using a standard Judkms technique Significant
coronary artery disease was defined as at least 50% luminal
stenosis m one or more major coronary artenes Although
the critena for selection of patients included only patients
with dilated cardiomyopathy that was chrncally Idiopathic
and excluded patients With any evidence of coronary artery
disease, two patients were found to have tnple vessel disease
and two to have double vessel disease at coronary angi-
ography Thus, although all 10 patients chmcally had IdIO-
pathic dilated cardiomyopathy, only 6 had normal coronary
angiograms and the other 4 had occult coronary disease
The study was approved by the Hospital Ethics Com-
mittee m December 1980 and informed wntten consent was
obtained from all patients
Protocol. The patients were tnutally admitted to the hos-
pital for a dose turation study Metoprolol was administered
openly With the startmg dose of 25 mg twice a day The
dose was increased in a stepwise manner over the following
week to a maximal dose of 100 mg twice dally or the
maximal dose tolerated, determmed by predefined end points
These end points were either a decrease m systolic blood
pressure to less than 100 mm Hg, a decrease m heart rate
at rest to less than 60 beats/rmn or cluneal detenoranon
After the completion of the dose titration studies, admm-
istranon of metoprolol was stopped and the patients were
discharged from the hospital for a washout penod of at least
2 weeks
After this 2 week penod, the patients underwent a base-
lme exercise study and then entered the double-blmd cross-
over phase, receiving either metoprolol or placebo in the
predetermined dosage for a 4 week treatment penod, With
a repeat study at the end of each treatment penod
The three exercise studies were Identical and consisted
of two exercise tests using the same electronically braked
bicycle ergometer The first test determined erect exercise
capacity and the second assessed cardiac function dunng
graded supine exercise Exercise capacity was measured by
a symptom-limited erect bicycle spnnt test With an minal
work load of 100 kpm/rmn and stepwise increments m work
load of 100 kpm/mm until the maximal tolerated work load
was achieved (5) Exercise was termmated by either dyspnea
or fatigue in all 10 patients On the following morrung, the
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patient underwent the second test, which was a graded su-
pine bicycle exercise test with three work loads of 20, 40
and 60%, respectively, of the maximal work load achieved
on the erect spnnt test of the baseline study Consequently,
in the mdividual patient, the three work loads used for
graded supine exercise were identical throughout the tnal
Each work load was of 4 minutes' duration The exercise
test was performed 1 hour after the adrmmstration of the
normal mormng dose of metoprolol and 2 to 3 hours after
adrrnrustration of the patient's routme medication for cardiac
failure, mcluding diuretic drugs In the last five patients,
blood was taken for plasma metoprolollevel determmanons
Just before the onset of exercise Metoprolol in plasma was
assayed with high pressure liquid chromatography with flu-
orescence detection by a method similar to that descnbed
by Bangah et al (6)
RIght heart cathetenzatton was performed under fluo-
roscopy using a thermodilution Swan-Ganz catheter on the
mormng of and before the supine exercise test Pulmonary
artery and left ventncular fillmg pressures and cardiac output
were measured at rest and dunng the last 2 minutes of each
4 mmute work load level of graded exercise Left ventncular
fillmg pressure was defined as either mean pulmonary artery
wedge pressure or pulmonary artery end-diastolic pressure,
If the former was unobtainable Thermodilution cardiac out-
put estimations were performed in tnphcate usmg Ice-cold
dextrose solutions
Equilibrium radtonuclide ventriculography was per-
formed in the left antenor oblique projection With the best
septal separation at a 15° caudal tilt Left ventncular ejection
fraction was calculated using a standard vanable region of
interest techmque Mean value (± standard deviation) for
the laboratory IS 67 ± 7% (7) Each acquisition was for 2
rmnutes at rest and for the last 2 minutes of each 4 mmute
work load level Exerctse was termmated by either the com-
pletion of the three work load levels or the symptoms of
dyspnea or fatigue
Heart rate and blood pressure (obtamed using a calibrated
sphygmomanometer) were recorded at rest and dunng the
last 2 mmutes of each 4 minute work load level Mean blood
pressure was calculated as Mean blood pressure = 2/, (DI-
astohc blood pressure) + 1/, (Systolic blood pressure)
Blood samples were obtamed on the day after the supine
exercise studies after overnight recumbency and agam after
2 hours of routme ambulatory actrvity, Plasma remn activity
was measured by radioimmunoassay (8) from venous sam-
pies With a reference range of 0 3 to 1 4 ng/ml per h re-
cumbent and 0 6 to 2 8 ambulant m sodium-replete normal
subjects
Statistical analysis. The data were analyzed by stepwise
regression analysis With the subject main effects bemg the
first factors entered into the equations Assessment of treat-
ment effects used all data both at rest and at all levels of
exercise and not Just matched data The main independent
vanables in the regression analysis were subject, work load,
work load squared, exercise study number, treatment type
and (treatment type) X (work load)
Loganthrruc transformation was used for the plasma rerun
activity All other vanables were approximately normally
distnbuted
Results
Clinical findings. The mean (± standard error of the
mean) dose of metoprolol achieved dunng the dose ranging
penod was 130 ± 13 mg With a rrummal dose of 50 mg
twice a day (Table 1) Two patients achieved the maximal
dose of 100 mg twice dally and m eight patients the dose
was less because of a decrease m heart rate to below 60
beats/min m seven patients and a decrease m systolic blood
pressure to below 100 mm Hg in one patient No patient
had chrucal detenoration dunng this penod
Nine of the 10 patients remained m functional class III
throughout the trial. however, compared With their status
dunng placebo adrmmstration, four felt slightly better With
metoprolol therapy, three felt slightly worse and two did
not nonce any change The condmon of the remammg pa-
nent (Patient 2) detenorated throughout the tnal, changing
to functional class IV dunng placebo treatment, which was
the second treatment given
Throughout the tnal period, medications for heart failure,
mcludmg digoxin, diurenc drugs and vasodilators, remained
unchanged There was no significant change m the patients'
weight, chest X-ray appearance, serum electrolyte esnma-
nons or renal function
Exercise tolerance. The mean maximal work loads ob-
tamed dunng the erect spnnt exercise test at each of the
three studies were not significantly different (baselme
700 ± 73, placebo 690 ± 85 and metoprolol 710 ± 81
kprn/mm [Fig 1]) The set work loads for the graded supine
exercise assessment of cardiac function. based on 20, 40
and 60% of the maximal work load achieved on the basel me
erect spnnt test, were 145 ± 17 kpm/rrun for the first graded
exercise level, 285 ± 35 for the second exercise level and
395 ± 56 for the third exercise level All 10 patients main-
tamed the first level of exercise, 9 reached the second and
6 reached the third level m all three studies Three of the
four patients who did not reach the third exercise level m
all three studies, reached this level in one or two studies
The data from these unpaired exercise levels were included
m the regression analysis
Hemodynamics (Fig. 2 and Table 2). There was a sig-
mficantly lower heart rate, both at rest and dunng exercise,
dunng metoprolol therapy compared WIth the baselme and
placebo studies (probability [p] < 0 001) The mean blood
pressure at rest and dunng graded exercise was not sigmf-
icantly different among the three studies Left ventncular
fillmg pressure increased sigmficantly WIth exercise (p <
o001), but there was no effect ot metoprolol when this
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Figure 1. Companson of the maximal work load (Wrnax) achieved
with the erect bicycle spnntexercise test In the basehne, placebo
and metoprolol studies Values shown are mean values ± standard
error of the mean
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Figure2. Mean heart rate (HR ), cardiac Index (Cl), left ventnc-
ular filling pressure (LVFP) and radionuchde left ventncular ejec-
tion fraction (L VEF) at rest and dunng graded supme bicycle
exercise (exercise [Ex) levels 1,2 and 3) In thebaselme, placebo
and metoprolol studies Standard error bars are depicted foronly
the placebo and metoprolol studies MetoproloI resulted In a sig-
nificant decrease In heart rate (p < 0 00 I) and cardiac tndex (p
< a 05), but there was no difference between the baseline and
placebo studies No significant difference was observed m left
ventncular fillmg pressure 10 the three studies, left ventncular
ejection fracnon was significantly lower in the baselme study (p
< 0 001), but there was no difference between the placebo or
metoprolol studies Figures in parentheses mdicate number of
subjects
Discussion
The reports of the beneficial effects of chronic beta-
adrenergic block109 therapy 10 patients With dilated cardio-
myopathy were made in uncontrolled studies by the group
from Sweden (1-4) They observed that chrome beta-
adrenergic blockade may produce significant Improvement
in symptoms and myocardial function m some patients With
dilated cardiomyopathy and recommended that all patients
With severe dilated cardiomyopathy have a tnal of beta-
adrenergic blockmg therapy
Effects of metoprolol. In our controlled study of pa-
tients With stable chronic dilated cardiomyopathy on vaso-
dilators, therapy With metoprolol for I month resulted m
no symptomatic Improvement or detenoration and no ob-
jective change in exercise capacity As expected, beta-
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study was compared with the two control studies, baseline
and placebo. Cardiac index overall was significantly lower
with metoprolol than dunng the two control studies when
work loads were considered (p < 0 05)
Left ventricular function variables (Fig. 2 and Table
2). Radionuchde left ventncular ejection fraction did not
change significantly with exercise There was a significant
increase m the ejection fraction values, pooled over rest and
exercise conditions, between the baseline study and the two
subsequent studies (p < 0 001) There was no difference
between the metoprolol and placebo studies
Stroke volume index was srgruficantly higher m the me-
toprolol treatment penod at rest and dunng exercise com-
pared with the baseline and placebo studies (p < 0.001)
Order of treatment. Five patients received placebo as
the first treatment and five patients received metoprololfirst
The order of treatment was found not to be a significant
factor, so that no addrtional sigmficant effects of treatment
could have been observed If analyses were restncted only
to first treatment penods
Coronary artery disease. When the four patients with
chmcally occult coronary artery disease were comparedWith
the remaming SIX patients, there was no significant differ-
ence in any of the measured vanabies
Plasma metoprolollevels. The plasma metoprolol lev-
els for Patients 6 to 10 are shown in Table I. The mean
metoprolol level was 80 ± 20 ng/ml These levels were
well within the range for near maximal cardiac beta-adreno-
receptor blockade (9)
Plasma renin activity. The plasma rerunactivity results
vaned Widely among patients There was a significant de-
crease m the recumbent plasma rerun with metoprolol (geo-
metnc means. baseline 2 4 ng/ml per h, placebo 2 0 versus
metoprolol I 2: p < 0 05) Ambulant plasma remn also
decreased significantly With metoprolol therapy (geometric
means baselme 7 9, placebo 7 2 versus metoprolol 3 4, P
< 0001)
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Table 2. Vanables of Cardiac Function at Rest and on Graded Supine Exercise m 10 Patients (mean ± standard errorof the mean)"
Second HIghest Common
Rest (n = 10) Work Load (n = 9) Maximal Common Work Load
Basehne Placebo Metoprolol Baseline Placebo Metoprolol Ba-elme Placebo Metoprolol
HR 82 ± 4 81 ± 3 61 ± 2 114 ± 4 114 ± 5 91 ± 3 135 ± 6 130 ± 6 103 ± 6
BP 95 ± 4 95 ± 5 93 ± 4 100 ± 3 104 ± 4 100 ± 4 110 ± 4 109 ± 5 107 ± 4
LVFP 16 ± 3 13 ± 3 16 ± 4 30 ± 5 25 ± 5 28 ± 6 33 ± 4 32 ± 5 33 ± 4
LVEF 27 ± 4 28 ± 4 31 ± 3 27 ± 5 30 ± 5 31 ± 4 27 ± 5 29 ± 5 29 ± 4
CI 25 ± 02 24 ± 02 24 ± 02 36 ± 03 35 ± 02 34 ± 03 38 ± 04 40 ± 03 37 ± 03
SVI 30 ± 2 30 ± 2 40 ± 3 32 ± 2 31 ± 2 36 ± 2 28 ± 2 28 ± 3 36 ± 2
*The maximal common work load I' the highest work load level achieved by each patient 10 all three studies This represents exercise level 3 10 SIX
panents exercise level 2 10 three patients and exercise level 1 10 the remaming patient. who therefore had no second highest level The second highest
common work load IS the second highest Identical work load level achieved and represents exercise level J 10 'IX patients and exercise level 1 In three
pattents Note that stanstical sigmficance oftreatment effects has been assessed by regression analysis which includes all data, mcluding those that could
not be shown 10 this table and not Just at rest and maximal exercise (see Stansncal Methods for explanation and Results torsigmncant differences)
BP = mean blood pressure (rnrn Hg), CI = cardiac mdex (hters/nun per rn'), HR = heart rate (beats/nun) LVEF = left ventricular ejecnon fraction
(%), LVFP = left ventncular nllmg pressure (rnm Hg), SVI = stroke volume index (rnl/rn')
adrenergic blockmg therapy produced a significant decrease
in heart rate There were no differences between the effect
of metoprolol and placebo on mean blood pressure, left
ventncular ejection fraction and left ventncular filling pres-
sure either at rest or dunng graded supme exercise How-
ever, metoprolol therapy produced a small but significant
reducnon in overall cardiac index compared With placebo
The significant reduction m heart rate at rest and dunng
exercise might have been expected to be associated With
higher left ventncular pressures, but these were not ob-
served Although these heart rate changes may have led to
some difficulty m mterpretmg the left ventncular filling
pressure results, the multiple other indexes of cardiac func-
tion recorded In this study were concordant m their failure
to show Improvement With metoprolol
In 9 of the 10 patients, there was no change In symptoms
or rest and exercise cardiac function dunng the penod sep-
aratmg the baselme and placebo studies, except for a small
but significant Increase in left ventncular ejecnon fraction
This Increase was not attnbutable to therapy because there
was no difference between the metoprolol and placebo stud-
res This finding emphasizes the Importance of having two
control penods when evaluatmg the effect of a drug on a
disease process that may vary With time The symptomatic
and objective detenoration of the condinon of the remaimng
patient (Patient 2) was continuous throughout the sequential
study penods It was considered that this detenoranon was
attnbutable to natural progression of the underlying disease
rather than to any effect of metoprolol
Comparison with earlier studies reporting bene-
fit. Patient groups Our results are, therefore, at vanance
With findings of the previously reported uncontrolled vtudy
(1,2). These differences are unlikely to be due to patient
selection because our study was designed WIth similar entry
cntena All 10patients Inour study had severe and clmically
rdiopathic dtlated cardiomyopathy WIth functional clas-, III
and low ejection fractions at rest and abnormal exercise
hemodynamic status The near normal rest left ventncular
filling pressures In our patients may be due to the diuretic
drugs and vasodilator therapy given on the mornmg of the
study The majority of patients (19 of 28 patients) in the
tnal of Swedberg et al (2) were also In functional class III
and 8 were in class IV, all patients had dtlated cardio-
myopathy thought to be rdiopathic chrucally The Impair-
ment of exercise tolerance In our patients was Similarto that
In the 18 patients of Swedberg et al (2) who had exercise
tests Direct comparisons are limited by the different ex-
erctse protocols used In the two studies However, It IS
established that the maximal work loads achieved using a
1 nun/stage spnnt protocol (5) are much higher than those
obtained With graded work loads of longer duration as m
the Swedish study Invasrve hemodynamic measurements
were reported by Swedberg et al m only 4 of their 28
patients and this was only at rest Only 14of their 28 patients
had coronary angiography. therefore, It IS possible that some
of their patients abo had unsuspected coronary disease In
our study, coronary angiography revealed unsuspected coro-
nary artery disease m 4 of 10 patients. but there was no
difference between these 4 patients and the 6 patients m the
measured vanables of cardiac function
Dose oj metoprolol and length oj follow-up period The
betaI-selective adrenergic blocking drug, metoprolol, used
In our study wav also the drug most frequently used by
Swedberg's group (2), either initially or as maintenance
therapy The adequacy of the dose of metoprolol used m
our study wavsupported by the dose ntranon protocol used.
by the highly srgmficant decrease m heart rate at rest and
dunng all levels of exercise and by the adequate plasma
metoprolol levels obtained I hour after the dose in the five
patients In whom there were measured (9) It IS possible
that the degree of beta-blockade would have been more
completely documented If assessment of response to a beta-
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receptor agomst had been performed This additional testmg
was not deemed necessary before exercise testing, partic-
ularly because It would not have been fully compatible with
the study's aim of determmmg the effect of I month ofbeta-
adrenergic blockade
Benefit from a therapy may require more than 1 month
to become mamfest and a longer penod of treatment may
be required to fully evaluate the long-term effects of a drug
However, Swedberg et al (2) reported that the beneficial
effects of oral beta-adrenergic blockade occurred within the
first month in most patients and that Improvement was stable
thereafter, It was for this reason that a 1 month treatment
penod was chosen for our study
Improved ejection fraction An Important observation m
our study was the small but significant Improvement m left
ventncular ejection fraction from the baseline value to the
two subsequent studies If the design of our study had not
allowed for the two control penods (baseline and placebo),
this Improvement might have been erroneously attnbuted to
metoprolol therapy It IS possible that the Improved left
ventncular ejection fraction noted in the uncontrolled study
of Swedberg et al (2) was due to the natural history of the
condition rather than the effect of beta-receptor blockade
Comparison with other controlled trials. Acebutolol
study Our results are in general agreement Withother con-
trolled tnals of oral beta-blocking therapy in patients With
dilated cardiomyopathy (10.11) A double-blmd study that
assessed the effects of I month of therapy Withanother beta-
adrenergic blocking drug, acebutolol, in patients Withsevere
dilated cardiomyopathy was reported by Ikram and Fitzpa-
tnck (10) Assessment was made With M-mode echocardi-
ography, exercise tolerance and maximal oxygen consump-
tion on exercise They found no Improvement With acebutolol.
However, their study IS not stnctly comparable WIth either
our study or that of Swedberg et al (2), because 12 of their
17 patients had alcoholic cardiomyopathy and only 5 had
Idiopathic cardiomyopathy by chmcal cntena They also
mcluded patients With less severe disease, With 7 of the 17
patients m functional class II and a mean echocardiograpluc
ejection fraction of 44 ± 5% compared With a mean of 32
± 2% in Swedberg et al (2) Furthermore, acebutolol,
although cardioselective, IS a beta-adrenergic blockmg drug
With mtnnsic sympathomimetic activity
Oxprenolol study Taylor et al (II) reported a single-
blind acute oral study With oxprenolol in eight patients With
severe heart failure due to inoperable coronary disease They
assessed hemodynamic status at rest and dunng exercise
With a Swan-Ganz catheter before and 1 hour after 20 mg
of oxprenolol and found all hemodynamic variables were
worsened They concluded that oxprenolol further depressed
left ventncular performance in their patients Despite the
significant differences m the study designs, the results of
Ikram et al (10) and Taylor et al (II) are m accord With
those of our study in showing no hemodynamic Improve-
ment after beta-adrenergic blocking therapy
Effect of concomitant drug therapy The failure of our
study to find either adverse or beneficial effects of beta-
adrenergic blocking therapy could possibly be related to the
effect of concomitant medications All patients m our study
were receiving vasodilators, whereas few If any patients in
the study by Swedberg et al (2) were receivmg vasodilators
It IS unknown to what degree concomitant vasodilator ther-
apy may prevent either a positive or negative effect of beta-
adrenergic blocking therapy on cardiac function The con-
comitant therapy With vasodilators m the study by Taylor
et al (11) did not prevent the detenoranon in hemodynamics
With oral beta-adrenergic blocking therapy DIUretic drug
therapy may have possibly masked an effect of metoprolol
on cardiac function m our study, but all of the patients in
the studies by Swedberg (2), Taylor (II) and their co-work-
ers were also receivmg diuretic drugs, and effects of beta-
blockade on cardiac function were still observed
Plasma renin levels It IS well known that many patients
With severe heart failure have elevated plasma remn levels
(12) A possible mechamsm of effect of metoprolol on pa-
tients With severe dilated cardiomyopathy has been postu-
lated to be related to suppression of the renm-angiotensm
system (13) We have shown m our study that although
recumbent and ambulatory plasma reruns levels were sig-
mficantly lower dunng treatment With metoprolol, this did
not produce any measurable effect on cardiac function
Implications. This study has not demonstrated the ad-
verse effects on cardiac performance that have been tradi-
tionally feared from beta-adrenergic blocking drugs when
used In the presence of severe heart failure, nor has It dem-
onstrated any beneficial effect on symptoms or cardiac func-
non We have confirmed earlier reports (2,10) that beta-
adrenergic blockmg drugs can be adrmmstered orally With-
out adverse effects to patients With stable cardiac failure
receivmg adequate treatment for cardiac failure Caution IS
still required in the use of beta-adrenergic blockmg drugs
m such patients, because neither this study nor those claim-
mg positive benefit have ehmmated the POSSibility of IdIO-
syncratic decompensation m individual patients No data
exist to show the safety of beta-adrenergic blockade dunng
acute heart failure as distinct from such therapy msntuted
after stabihzanon
We thank Jan Stockigt, MD and FIOnaLong, SRN for remn measurements,
Ken MIddlebrook, MICTA for technical assistance, Graham Jackman,
MD, PhD tor plasma metoprolol measurements and George Renme for
statistical advice
References
Waagstem F, Hjalmarson A, Varnauskas E, Wallcntm I Effect of
chronic beta-adrenergic receptor blockade m congestive cardio-
myopathy Br Heart J 1975,37 1022-36
JACC Vol 3, No I
January 1984 203-9
CURRIE ET AL
METOPROLOL IN DILATED CARDIOMYOPATHY
209
2 Swedberg K, Hjalrnarson A, Waagstem F, Wallennn I Beneficial
effects of long term beta-blockade m congestivecardiomyopathy Br
Heart J 1980,44 117-33
3 Swedberg K, Hjalmarson A, WaagstemF, Wallentm I Adverse effects
of beta-blockade withdrawal in patients with congestive cardio-
myopathy Br Heart J 1980,44134-42
4 Swedberg K. WaagstemF, Hjarlmarson A, Wallentm I Prolongation
of survival m congestive cardiomyopathy by beta-receptor blockade
Lancet 1979,1 1374-6
5 Bailey IK, Anderson SD, Rozea PJ, BernstemL, Nyberg G, Korner
PI Effectof beta-adrenergic blockadewith alprenolol on ST-segment
depression and circulatory dynamics dunng exercise m patients with
effort angma Am Heart J 1976,92416-26
6 BangahM, JackmanG, BobikA Determination of pmdololin human
plasma by high performance hquid chromatography J Chromatogr
1980,183255-9
7 Kalff V, Kelly MJ, JenningsGL, et al The radionuchde assessment
of left ventncular function using graded exercise in normal subjects
Aust NZ J Med 1980,10533-9
8 Stockigt J. Collins R, Noakes C, Schambelan M. Bighen E Renal
veinrerun measurement m vanous formsof renalhypertension Lancet
1972,11194-8
9 Jenmngs G, Bobik A. Korner P Influence of mtnnsic sympathomi-
metic actrvity of beta-adrenoreceptor blockers in the heart rate and
blood pressure responses to graded exercise Br J Chn Pharrnacol
1981.\2 355-62
10 IkramH, FitzpatnckD Double-blind tnal of chronic oral beta block-
ade in congestive cardiomyopathy Lancet 1981,2490-2
II Taylor SH, Silke B Haemodynarrnc effects of beta-blockade m isch-
enuc heart disease Lancet 1981,2 835-7
12 Brown JJ. Davis DL, Johnson VW, Lever AF, Robertson JIS Rerun
relatronshrp m congestive cardiac failure. treated and untreated Am
Heart J 1970,80 329-42
13 Wetzel R Beta-adrenergic blockade in congesnve cardiomyopathy
(letter) Lancet 1980.1 1031
